
|Articles|May 28, 2015
- Genitourinary (Issue 2)
- Issue 2
Use of ARN-509 in Prostate Cancer
Author(s)Charles J. Ryan, MD
Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the use of ARN-509 and its efficacy in treating prostate cancer.
Advertisement
Articles in this issue
over 10 years ago
Abiraterone Plus Low-Dose Prednisone Lowers PSA in High-Risk M0 CRPCover 10 years ago
Study Illuminates Role of AR-V7 in Carcinogenesisover 10 years ago
PSA Screening Drops 50% Following USPSTF Recommendationover 10 years ago
Urine-Based Diagnostic Effectively Identifies Prostate Cancerover 10 years ago
Trends in PSA Utilization in Primary Care Physiciansover 10 years ago
AR-V7 as a Biomarker in CRPCAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































